Anadrol and SLU-PP-332 Interaction: Avoid | Peptide Database

MENT is being investigated as an alternative to testosterone for androgen replacement. Its high potency allows for low-volume injections, and unlike nandrolone it maintains sexual function without requiring a concurrent testosterone base. Subdermal implant formulations have been studied to provide sustained release over months, potentially offering a more convenient delivery method than testosterone injections. MENT's primary clinical research focus. Phase 2 trials have demonstrated that MENT, alone or in combination with a progestin, can suppress spermatogenesis to azoospermia or severe oligospermia in the majority of men. The contraceptive effect is reversible upon discontinuation. MENT's advantage over testosterone-based contraceptive approaches is its greater potency and the fact that it does not require 5-alpha reduction for full androgenic activity. MENT produces significant dose-dependent increases in lean body mass. Due to its potency being roughly 10 times that of testosterone, even low doses (5-10 mg/day) can produce anabolic effects comparable to moderate doses of testosterone. Higher doses (15-25 mg/day) produce substantial muscle growth but with increased side effect burden, particularly estrogenic effects. Users consistently report rapid and significant strength increases on MENT, often noticeable within the first 1-2 weeks due to the fast-acting acetate ester. Strength gains appear to scale with dose and are accompanied by notable improvements in training recovery. Unlike nandrolone and trenbolone (other 19-nor compounds), MENT maintains libido and erectile function because it acts directly on androgen receptors in the brain and sexual tissues without being reduced to a weaker metabolite. Many users report enhanced libido on MENT, particularly at lower doses before estrogenic side effects become prominent.

FDA-approved at 1mg daily for the treatment of male pattern hair loss. Demonstrated to halt progression and promote regrowth, particularly at the vertex and mid-scalp regions. Strongest clinical evidence for regrowth in the vertex region, with significant increases in hair count documented in pivotal clinical trials. Effective at slowing frontal hairline recession and maintaining mid-scalp density, though regrowth tends to be less dramatic than at the vertex. Most effective when started early in the hair loss process, before significant miniaturization has occurred. Preservation of existing hair is more reliable than regrowth of lost hair. FDA-approved at 5mg daily (Proscar) for the treatment of symptomatic BPH. Reduces prostate volume and improves urinary flow over 6-12 months of treatment. Consistently reduces prostate volume by approximately 20-30% with long-term use, alleviating obstructive urinary symptoms.